Sonoma Pharmaceuticals & MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered...
28 Mai 2020 - 10:30PM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
eye care and dermatological conditions, and its partner, the
MicroSafe Group, Dubai, announce an important break-through in the
fight of the global coronavirus pandemic. MicroSafe Care Australia
received approval for their patented and trademarked Nanocyn®
Disinfectant & Sanitizer, which is manufactured by Sonoma using
its patented Microcyn® Technology, to be entered into the
Australian Register of Therapeutic Goods (ARTG) for use against
SARS-CoV-2 (COVID-19). Claims that a disinfectant has a virucidal
effect must be expressly permitted by the Australian Therapeutic
Goods Administration before being used in consumer advertising
(including on the label) in Australia.
Recently, Sonoma announced that it had successfully closed an
Asset Purchase Agreement with MicroSafe Group, for the exclusive
rights of the Microcyn® technology-based disinfectant for sale in
the Australian market under the brand name Nanocyn® and the
European and Middle Eastern markets under the brand name
MicroSafe®.
“We have been fighting global pandemics for nearly 20 years with
our safe and non-toxic Microcyn® based disinfectant and we are very
pleased with the test results and subsequent approval of the
SARS-CoV-2 (COVID-19) label claim for our Nanocyn® disinfectant in
Australia. The label claim comes with a 30 second virucidal kill
time on hard surfaces, a landmark kill time for a non-toxic
disinfectant,” Mrs. Safa Qadumi, Founder and CEO of the MicroSafe
Group Dubai, said.
“We have known for years that our Microcyn® Technology is
effective against a number of pathogens, including viruses, so we
are pleased to get this acknowledgement from the ARTG that our
technology is effective in killing COVID-19,” said Amy Trombly, CEO
of Sonoma Pharmaceuticals. She continued, “As the pandemic has
spread around the world, we are excited to work with partners like
MicroSafe Group to provide a safer environment for people during
this difficult time. As an international company selling products
in 53 countries around the world, we are continuously seeking
additional partners to expand our domestic and global reach in
distributing our products.”
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, oral care and dermatological
conditions. The company’s products reduce infections, itch, pain,
scarring and harmful inflammatory responses in a safe and effective
manner. In-vitro and clinical studies of hypochlorous acid (HOCl)
show it to have impressive antipruritic, antimicrobial, antiviral
and anti-inflammatory properties. Sonoma’s stabilized HOCl
immediately relieves itch and pain, kills pathogens and breaks down
biofilm, does not sting or irritate skin and oxygenates the cells
in the area treated assisting the body in its natural healing
process. The company’s products are sold either directly or via
partners in 53 countries worldwide and the company actively seeks
new distribution partners. The company has offices in Petaluma,
California and Woodstock, Georgia, with manufacturing operations in
the United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com. For partnership opportunities,
please contact businessdevelopment@sonomapharma.com.
About MicroSafe Group
The MicroSafe Group has operations in several international
countries with its head office in Dubai, United Arab Emirates. With
several regional offices in the Middle East, as well as MicroSafe
Care Australia, MicroSafe Group is able to provide innovative
solutions to a wide range of industries and healthcare providers.
The MicroSafe Group promotes only those products it believes will
truly revolutionize healthcare – products that will enrich the
lives of patients and healthcare professionals all over the world.
Interested distributors may contact the MicroSafe Group at
info@microsafecare.com. More information can be found at
www.microsafe.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “promise,” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks
resulting from the global COVID-19 pandemic, that regulatory
clinical and guideline developments may change, scientific data may
not be sufficient to meet regulatory standards or receipt of
required regulatory clearances or approvals, clinical results may
not be replicated in actual patient settings, protection offered by
the company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the company’s products will not be as large as expected,
the company’s products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to meet the
company’s cash needs, fund further development and clinical
studies, as well as uncertainties relative to varying product
formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other
risks detailed from time to time in the company’s filings with the
Securities and Exchange Commission. The company disclaims any
obligation to update these forward-looking statements, except as
required by law.
Sonoma Pharmaceuticals™, Microcyn® and Microdacyn60® are
trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc.
All other trademarks and service marks are the property of their
respective owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200528005780/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
Von Mär 2023 bis Mär 2024